Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
8.85    -0.22 (-2.50%)
Bid:
8.50
Ask:
9.20
Spread: 0.70 (8.235%)
Market Cap: £56.22m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

Progress with global OEM contract

22 Sep 2014 07:00

RNS Number : 1959S
Kromek Group PLC
22 September 2014
 



22 September 2014

 

Kromek Group plc

("Kromek" or the "Company")

 

Kromek Progresses to Second Year of Development Contract with Global OEM in CT Medical Imaging Markets

 

Kromek, a radiation detection technology company focusing on the medical, security and nuclear markets, is pleased to announce that a top four Original Equipment Manufacturer ("OEM") in the Computed Tomography ("CT") market has confirmed its decision to progress to the second year of a previously announced programme with the Company. Kromek has received a $1m exclusivity payment for the second year.

 

This payment is part of a programme that comes under Kromek's mutually exclusive development contract, worth up to $5.3m, with the OEM for developing and supplying Cadmium Zinc Telluride ("CZT") based multispectral (colour) detectors for producing high resolution colour X-Ray images by CT scanners. The decision to continue the programme for the second year was based on sustained progress towards meeting the aims of the development programme.

 

Arnab Basu, CEO of Kromek, said: "We are delighted to be progressing this project to advance colour CT imaging, which can lead to major healthcare benefits for diagnosis and treatment of cancers, cardiovascular diseases and other pathologies. With the success of our collaboration, our relationship with this key OEM partner continues to develop and grow stronger. This latest step is a clear endorsement of our technology and our long-term strategy to position Kromek's subcomponents at the heart of major global OEMs' medical imaging systems to improve diagnostic capabilities, resulting in better clinical outcomes."

 

This contract does not change the Company's expectations for the year ended 30 April 2015. However, it provides further evidence of the progress towards meeting market expectations.

 

Arnab Basu, CEO, and Derek Bulmer, CFO, will be hosting a webinar today at 12pm where they will give a presentation on their results for the year ended 30 April 2014. No additional disclosure will be made about financials or current trading further to the Company's announcement released on 28 August 2014. Analysts and investors wishing to join can register at:

https://attendee.gotowebinar.com/register/5530034774550287105

Enquiries

 

Kromek Group plc

Arnab Basu, CEO

Derek Bulmer, CFO

01740 626 060

Panmure Gordon (Nominated Adviser and Broker)

Freddy Crossley - Corporate Finance

Charles Leigh-Pemberton - Broking

0207 886 2500

Luther Pendragon

Harry Chathli, Claire Norbury, Alexis Gore, Ivana Petkova

0207 618 9100

 

 

 

About Kromek Group plc

 

Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT"). Using its core CZT technology Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

 

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

 

Kromek uses multiple technologies in its manufacturing processes, including the established methods of 'liquid phase' detector production, and also 'vapour phase' production methods, which allow the production of high quality, high performance detectors on an industrial scale. Kromek has an intellectual property portfolio of more than 250 pieces of IP.

The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

 

The Board believes that the vertical integration offered by Kromek, combined with the benefit of 25 years of research into CZT production and the patents and trade secrets accumulated by the Group, are unparalleled in the market place.

 

The Group has operations in the UK, Germany and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

 

Currently, the Group has over a hundred full time employees across its global operations.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTEAENFADDLEAF
Date   Source Headline
4th Apr 20227:00 amRNSNew £1.7m CBRN contract
18th Jan 20227:00 amRNSInterim Results
17th Dec 20214:41 pmRNSSecond Price Monitoring Extn
17th Dec 20214:35 pmRNSPrice Monitoring Extension
14th Dec 20217:00 amRNSNotice of Results
26th Oct 20217:00 amRNSKromek awarded contract by US based OEM customer
29th Sep 20213:14 pmRNSHolding(s) in Company
27th Sep 20211:47 pmRNSDirector Share Purchase
23rd Sep 20217:00 amRNSNuclear security contract from US federal entity
8th Sep 202111:09 amRNSResult of AGM
13th Aug 20213:48 pmRNSNotice of AGM and Publication of Annual Report
3rd Aug 202112:25 pmRNSHolding(s) in Company
15th Jul 202111:05 amRNSSecond Price Monitoring Extn
15th Jul 202111:00 amRNSPrice Monitoring Extension
14th Jul 20217:00 amRNSFinal Results
14th Jul 20217:00 amRNSNew Contracts
1st Jul 20217:00 amRNSNotice of Results
24th Jun 20214:41 pmRNSSecond Price Monitoring Extn
24th Jun 20214:36 pmRNSPrice Monitoring Extension
14th Jun 20217:00 amRNSKromek awarded new DARPA bio-threat contract
12th May 20212:50 pmRNSDirector Share Purchase
11th May 20217:00 amRNSBusiness and Trading Update
21st Apr 20214:32 pmRNSHolding(s) in Company
9th Mar 20217:00 amRNSKromek awarded Nuclear Detection contract
4th Mar 20211:32 pmRNSHolding(s) in Company
2nd Mar 20218:30 amRNSPDMR Dealings
1st Mar 20212:53 pmRNSResults of Placing, Open Offer and General Meeting
1st Mar 20217:00 amRNSNew Medical Screening and Nuclear Security orders
19th Feb 20212:05 pmRNSSecond Price Monitoring Extn
19th Feb 20212:01 pmRNSPrice Monitoring Extension
15th Feb 20217:00 amRNSPosting of Circular
12th Feb 202111:05 amRNSSecond Price Monitoring Extn
12th Feb 202111:00 amRNSPrice Monitoring Extension
12th Feb 202110:30 amRNSPlacing and Open Offer to raise up to £13 million
4th Feb 20212:00 pmRNSIssue of Equity and Total Voting Rights
26th Jan 20215:15 pmRNSHolding(s) in Company
22nd Jan 20214:41 pmRNSSecond Price Monitoring Extn
22nd Jan 20214:35 pmRNSPrice Monitoring Extension
22nd Jan 20212:05 pmRNSSecond Price Monitoring Extn
22nd Jan 20212:00 pmRNSPrice Monitoring Extension
14th Jan 20214:41 pmRNSSecond Price Monitoring Extn
14th Jan 20214:35 pmRNSPrice Monitoring Extension
14th Jan 20219:35 amRNSHolding(s) in Company
13th Jan 20217:01 amRNSFunding to advance Bio-Threat Detection solution
13th Jan 20217:00 amRNSInterim Results
7th Jan 202111:05 amRNSSecond Price Monitoring Extn
7th Jan 202111:01 amRNSPrice Monitoring Extension
16th Dec 20207:00 amRNSDirectorate Changes
14th Dec 202012:45 pmRNSHolding(s) in Company
8th Dec 20207:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.